Literature DB >> 22672818

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.

Onur Yaprak1, Murat Akyildiz, Murat Dayangac, Baha Tolga Demirbas, Necdet Guler, Gulen Bulbul Dogusoy, Yildiray Yuzer, Yaman Tokat.   

Abstract

BACKGROUND: In liver transplantation or resection for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation.
METHODS: In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively from the Organ Transplantation Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic staging criteria (Milan and UCSF), etiology, number of tumors, the largest tumor size, total tumor size, multifocality, intrahepatic portal vein tumor thrombosis, bilobarity, and histological differentiation.
RESULTS: One hundred and two patients were evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with fibrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5+/-6.9 years. Sixty-two patients underwent living donor liver transplantations. The mean follow-up time was 29.4+/-22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were significant factors related to survival and tumor recurrence.The 5-year estimated overall survival rate was 62.2% in all patients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors.
CONCLUSIONS: For proper patient selection in liver transplantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672818     DOI: 10.1016/s1499-3872(12)60157-x

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  12 in total

1.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

2.  Child-Pugh A hepatitis B-related cirrhotic patients with a single hepatocellular carcinoma up to 5 cm: liver transplantation vs. resection.

Authors:  Chuan Li; Wen-Jiang Zhu; Tian-Fu Wen; Yan Dai; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Ming-Qing Xu
Journal:  J Gastrointest Surg       Date:  2014-06-06       Impact factor: 3.452

3.  Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.

Authors:  Asmaa I Gomaa; Alzhraa Al-Khatib; Wael Abdel-Razek; Mohammed Saad Hashim; Imam Waked
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

4.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 5.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 6.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

7.  Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study.

Authors:  Ulus Salih Akarca; Belkis Unsal; Orhan Sezgin; Kendal Yalcin; Meral Akdogan; Can Gonen; Feyza Gunduz; Seren Ozenirler; Abdullah Sonsuz; Dinc Dincer; Salim Basol Tekin; Idris Yucel; Hakan Akbulut; Canan Alkım; Ozgur Ozyilkan; Arzu Baygul; Zeynep Merve Cevik; Ramazan Idilman; On Behalf Of K Registry Study Group
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

8.  Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades.

Authors:  Lei Zhang; Ya Huang; Mingjian Lian; Zhijuan Fan; Yaqiong Tian; Yufan Wang; Hua Kang; Shuang Liu; Shuye Liu; Tong Li; Zhongqiang Shan
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

9.  Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.

Authors:  Nan Zhang; Jiajia Gu; Li Yin; Jing Wu; Ming-Yu Du; Kai Ding; Teng Huang; Xia He
Journal:  Oncotarget       Date:  2016-12-06

10.  Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.

Authors:  Luciana Dos Santos Schraiber; Angelo Alves de Mattos; Maria Lucia Zanotelli; Guido Pio Cracco Cantisani; Ajácio Bandeira de Mello Brandão; Cludio Augusto Marroni; Guilhermo Kiss; Lucas Ernani; Patrícia Dos Santos Marcon
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.